Adalimumab biosimilar (Bio-Thera Solutions)

阿达木单抗生物类似药（百奥泰生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Bio-Thera Solutions)
Drug Alias Name重组人抗TNF-α单抗（百奥泰生物）QLETLI阿达木单抗生物仿制药（百奥泰生物）格乐立BAT-1406
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisUveitisCrohn Disease +[5] 
Global Approved IndicationsPsoriasisUveitisCrohn Disease +[5] 
Approved Indications in ChinaPsoriasisUveitisCrohn Disease +[5] 
Original Approved Country/TerritoryMainland China
Original Approved Date2019/11/04
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBio-Thera Solutions Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisUveitisCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A